Search

Author/Creator Laskin, Carl A

3. Complement activation predicts adverse pregnancy outcome in patients with systemic lupus erythematosus and/or antiphospholipid antibodies. Issue 4 (25th January 2018)

Authors:
Kim, Mimi Y; Guerra, Marta M; Kaplowitz, Elianna; Laskin, Carl A; Petri, Michelle; Branch, D Ware; Lockshin, Michael D; Sammaritano, Lisa R; Merrill, Joan T; Porter, T Flint; Sawitzke, Allen; Lynch, Anne M; Buyon, Jill P; Salmon, Jane E
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77:Issue 4(2018)
Page Start:
549
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus. Issue 12 (8th October 2018)

Authors:
Barsalou, Julie; Costedoat-Chalumeau, Nathalie; Berhanu, Adey; Fors-Nieves, Cesar; Shah, Ummara; Brown, Patrick; Laskin, Carl A; Morel, Nathalie; Levesque, Kateri; Buyon, Jill P; Silverman, Earl D; Izmirly, Peter M
Journal:
Annals of the rheumatic diseases
Issue:
Volume 77:Issue 12(2018)
Page Start:
1742
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Lupus anticoagulant is the main predictor of adverse pregnancy outcomes in aPL-positive patients: validation of PROMISSE study results. (12th January 2016)

Authors:
Yelnik, Cecile M; Laskin, Carl A; Porter, T Flint; Branch, D Ware; Buyon, Jill P; Guerra, Marta M; Lockshin, Michael D; Petri, Michelle; Merrill, Joan T; Sammaritano, Lisa R; Kim, Mimi Y; Salmon, Jane E
Journal:
Lupus science & medicine
Issue:
Volume 3(2016)Supplement 1
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗